Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis

Authors:

Abstract
Quiz Ref ID Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. Approximately 80% of patients with generalized MG have autoantibodies against the muscle nicotinic acetylcholine receptor (AChR) measured by radioimmunoprecipitation assay (RIPA).1,2 The AChR antibodies are predominantly IgG1 and IgG3 subclasses and produce severe loss of AChRs by complement-mediated damage to the postsynaptic membrane, receptor endocytosis, and occasionally direct AChR block.3 These patients are classically referred to as having seropositive MG. Quiz Ref ID Other patients with generalized MG and 50% of those with ocular MG lack detectable AChR antibodies by RIPA.4

This publication has 39 references indexed in Scilit: